Why the study?
Does PAI-1 inhibition prevent adverse tissue remodeling in rodent models of cardiovascular diseases?
Does PAI-1 inhibition prevent adverse tissue remodeling in rodent models of cardiovascular diseases?
PAI-1 inhibitors show potential in preventing adverse cardiovascular tissue remodeling in preclinical rodent models, though further research is needed due to the protein's multifunctional nature.
Answers are grounded in this paper and cite their sources.
PAI-1 inhibition remains preclinical; leaves open translation to human cardiovascular remodeling.
INTRODUCTION: plasminogen activator inhibitor-1 (PAI-1) is critical in thrombus formation and inflammation. Although these are essential pathological features of cardiovascular diseases, the effects of PAI-1 inhibition against the development of cardiovascular remodeling have not been well studied. AREAS COVERED: the review explores the therapeutic value of PAI-1 in the progression of various cardiovascular diseases. To date, the authors have reported that a novel PAI-1 inhibitor suppressed the development of experimental autoimmune myocarditis, vascular remodeling after arterial injury, and heart transplant rejection using rodent models. Pathologically, the PAI-1 inhibitor improved histological remodeling of myocardium and arteries with suppression of inflammation and thrombus formation. EXPERT OPINION: PAI-1 inhibitors appear to exhibit potent effects on the prevention of adverse tissue remodeling. However, PAI-1 is a multifunctional protein and more research is needed to further elucidate the association between PAI-1 expression and cardiovascular disease.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (2011) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: